Publication

Evaluation of two urinary RNA biomarker tests with an epigenetic DNA assay for the identification of men with high-grade prostate cancer

Trooskens G, et al. J Urol 2018;199 (Suppl):e610(abs. MP46-11)

 

What was studied?

The study investigated the complementarity between the SelectMDx test, performed before a biopsy, and the ConfirmMDx test, performed after a biopsy.

 

What were the main outcomes?

Combining SelectMDx with ConfirmMDx significantly improved the accuracy for detecting high-grade prostate cancer.

Both SelectMDx and ConfirmMDx had a better diagnostic accuracy for high-grade prostate cancer than PCA3.

 

Table. Diagnostic accuracy of biomarker tests to detect high-grade (Gleason score ≥7) prostate cancer on biopsy

Biomarker test

AUC

SelectMDx

0.88

ConfirmMDx

0.91

SelectMDx + ConfirmMDx

0.93

PCA3

0.73

AUC: area under the curve      

 

What was concluded?

SelectMDx and ConfirmMDx outperformed PCA3 for the detection of high-grade prostate cancer. Combining both tests further improves the accuracy for detecting high-grade prostate cancer

 

How was the study performed?

This study included 214 men who underwent a 12-core prostate biopsy. Urine samples were collected before the biopsy to perform the SelectMDx test and the PCA3 test. After the biopsy, biopsy tissue samples from all cores were tested with the ConfirmMDx test.

Stay informed about new biomarker updates

Fields wrapper
Country

Get a free test

Get started
* Required fields